Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Howard Marks dissects market madness, separating price from value, and warns investors: fundamentals are fading while ...

Trump's flip-flopping on Intel highlights the impact of politics on investor sentiment. New leadership, government investment ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.65, with a ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $5.56, along ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Nvidia's China woes have major implications for tech ETFs as Beijing pressures firms to use domestic alternatives. Near-term ...

The Social Security Administration recently announced the addition of 13 conditions to its Compassionate Allowances list, a ...

Needham analyst initiates AeroVironment at Buy with a $300 target, citing drone market growth, BlueHalo deal and rising ...

Medtronic reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of ...

Analysts expect the Dublin, Ireland-based company to report quarterly earnings at 29 cents per share. James Hardie Industries ...

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...